A bespoke QA programme was created for the 5 anatomical treatment sites which included spine and nodal metastasis. Prior to treatment centres were required to complete a QA process which included planning benchmark cases. Participating centres were provided with a pre-outlined planning CT. They created PTV expansions using local protocols. The centres were then required to create a plan based on a 30 Gy in 3 fraction prescription for the nodal case and a 24 Gy in 3 fractions prescription for the spine case. Both cases required a D95% of the prescription dose for the PTV coverage whilst ensuring OAR tolerances were met. All planning benchmarks were submitted and centrally analysed using VODCA 5.4 plan review software. The coverage of the PTV and CTV with the prescription dose, doses to OARs and measures of conformity were calculated. The values for the different submissions were compared to ensure plans were of suitable quality and comparable across different treatment platforms.
A 2 tail Mann-Whitney test was performed on the PTV coverage data for both plans. This indicated that there was a significant difference between cyberknife and VMAT plans (p=0.02).
Conclusion:
Cyberknife plans on average achieved superior PTV coverage when compared to VMAT plans. This was more evident for the spine PTV and nodal PTV 1, with both volumes being close to OARs, than for the nodal PTV 2 where OARs did not restrict the dose . The VMAT plans involved larger PTV and PRV expansions which would partly explain the difficulty in achieving the required PTV coverage. However, several of the VMAT plans had similar PTV coverage to the cyberknife plans, hence the greater variation in PTV coverage of the VMAT plans may reflect possible inexperience in SABR planning for some centres. Following resubmissions, all centres participating in the CtE programme have been able to produce acceptable benchmark plans regardless of treatment platform. Material and Methods: Xenograft models were established by injecting human derived glioblastoma multiforme stem-like cells in immunocompromised NOD-SCID mice both subcutaneously (10 groups) and intracranially (7 groups). Mice of each group were anesthetized and placed in a plexiglas cage pie to perform CT scans for treatment planning purposes. Target volumes and organs at risk (OARs) where outlined on CT scans: for subcutaneous xenografts, target volumes were delineated on the right flank and contoured OARs were lung and gastro-intestinal tract. For orthotopic models, a ring-shaped target structure was delineated on mice's head; contoured OAR was lung. Three fractionation schedules were tested: 4Gy/1 fraction, 4 Gy/2 fractions and 6 Gy/3 fractions. TomoDirect IMRT technique was applied, with gantry fixed at 0° and 180. 5 subcutaneous and 1 orthotopic groups of xenografts were irradiated by covering the target volume with a 0.6 cm bolus layer in order to reduce the impact of the build-up effect. Irradiations originally performed without bolus were simulated with a 0.6 cm virtual bolus in order to compare dosimetric results. Before irradiation, a MVCT image has been acquired to correct irradiation setup. Mice were observed daily and sacrificed when they showed signs of suffering or when tumour volume reached the established endpoint. Different radiobiological outcomes were evaluated, regarding both radiotoxicity (survival experiments) and tumour response (assessed by caliper or bioluminescence imaging), comparing irradiated mice as respect to their controls.
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Results: Dosimetric results showed that the presence of the bolus layer significantly impact the maximum dose received by both target volumes and OARs (t-test, p<0.05). Survival analysis showed that irradiation with a dose of 6 Gy in 3 fractions in the presence of a bolus layer prolong mice survival (Log-rank test, p<0.02), showing to be the safest irradiation protocol. Tumour volume response and mice survival were significantly different in irradiated xenografts as compared to their controls (t-test, p<0.03; Log-rank, p<0.05) demonstrating also the radiobiological potential of Tomotherapy in inducing tumour growth stabilization.
Conclusion:
Tomotherapy systems may be a useful mean for small animal irradiation. 
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